EGFR, HER2/neu and Ki67 immunoexpression in serous ovarian tumors

被引：0
作者：
Marinas, M. C. [1 ]
Mogos, G. [2 ]
Ciurea, Raluca [3 ]
Mogos, D. G. [2 ]
机构：
[1] Emergency Cty Hosp, Dept Obstet & Gynecol, Craiova, Romania
[2] Univ Med & Pharm Craiova, Dept Gen Surg, Craiova, Romania
[3] Univ Med & Pharm Craiova, Dept Pathol, Craiova, Romania
来源：
ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY | 2012年 / 53卷 / 03期
关键词：
ovarian serous tumor; EGFR; HER2/neu; Ki67; immunohistochemistry; GROWTH-FACTOR RECEPTOR; PROGNOSTIC-SIGNIFICANCE; CARCINOMA; HER-2/NEU; CANCER; EXPRESSION; P53; OVEREXPRESSION; BORDERLINE; PROTEIN;
D O I：
暂无
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
In this study, we analyzed EGFR, HER2/neu and Ki67 immunoexpression for 26 benign, borderline and malignant serous ovarian tumors. EGFR and HER2/neu immunoreactions were present in some benign/borderline tumors with high/low intensity of immunostain. In poorly differentiated adenocarcinomas, the EGFR/HER2/neu reaction was intense compared to well-differentiated ones. The Ki67 medium proliferation index was 2.1% for benign tumors, 6% in the borderline and 47.7% in malignant tumors. EGFR, HER2/neu and Ki67 can be used to identify benign/borderline tumors with progression potential and the malignant aggressive tumors.
引用
收藏
页码：563 / 567
页数：5
相关论文
共 15 条
  • [1] Epidermal growth factor receptor expression in serous ovarian carcinoma: An immunohistochemical study with galectin-3 and cyclin D1 and outcome
    Brustmann, Hermann
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2008, 27 (03) : 380 - 389
  • [2] HER-2 and cancer antigen 125 evaluation in ovarian borderline tumors by immunohistochemistry and fluorescence in situ hybridization
    Heinrich, JKR
    Böttcher-Luiz, F
    Andrade, LLA
    Davidson, S
    Bonds, L
    Stephens, J
    Varella-Garcia, M
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (06) : 1078 - 1085
  • [3] Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma
    Lassus, Heini
    Sihto, Harri
    Leminen, Arto
    Joensuu, Heikki
    Isola, Jorma
    Nupponen, Nina N.
    Butzow, Ralf
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2006, 84 (08): : 671 - 681
  • [4] Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer
    Nielsen, JS
    Jakobsen, E
    Holund, B
    Bertelsen, K
    Jakobsen, A
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (06) : 1086 - 1096
  • [5] Immunophenotyping of serous carcinoma of the female genital tract
    Nofech-Mozes, Sharon
    Khalifa, Mahmoud A.
    Ismiil, Nadia
    Saad, Reda S.
    Hanna, Wedad M.
    Covens, Al
    Ghorab, Zeina
    [J]. MODERN PATHOLOGY, 2008, 21 (09) : 1147 - 1155
  • [6] O'Neill CJ, 2005, AM J SURG PATHOL, V29, P1034
  • [7] HER-2/neu and bcl-2 in ovarian carcinoma - Clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival
    Raspollini, Maria Rosaria
    Amunni, Gianni
    Villanucci, Alessandro
    Castiglione, Francesca
    Degl'Innocenti, Duccio Rossi
    Baroni, Gianna
    Paglierani, Milena
    Taddei, Gian Luigi
    [J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2006, 14 (02) : 181 - 186
  • [8] Skirnisdóttir I, 2001, INT J GYNECOL CANCER, V11, P119, DOI 10.1046/j.1525-1438.2001.00086.x
  • [9] A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging
    Skírnisdóttir, I
    Seidal, T
    Sorbe, B
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (02) : 259 - 270
  • [10] Epithelial growth factor receptor status in primary and recurrent ovarian cancer
    Stadlmann, S
    Gueth, U
    Reiser, U
    Diener, PA
    Zeimet, AG
    Wight, E
    Mirlacher, M
    Sauter, G
    Mihatsch, MJ
    Singer, G
    [J]. MODERN PATHOLOGY, 2006, 19 (04) : 607 - 610
12